Ir al contenido principal

Cigna asume el pago de Luxturna y Zolgensma


Leo en Fiercepharma que Cigna dice se va a hacer cargo de los costes de administrar Luxturna y Zolgensma a sus clientes que lo necesiten. A su vez Cigna confirma la información:

Our intention is to include Luxturna™ (voretigene neparvovec-rzyl), the first FDA-approved prescription gene therapy for people with inherited retinal disease, and Zolgensma® (onasemnogene abeparvovec-xioi), a gene therapy for children under 2 years old with spinal muscular atrophy, in the Embarc Benefit Protection solution. Additional therapies may be added in the future.

Cigna dice en su web que es "a global health service company with 95 million customers around the world and more than 40,000 employees worldwide".

Respecto a sus números dice en su web:
Total revenues for 2018 were $49 billion. Adjusted revenues1 were $48 billion, an increase of 15% over 2017, driven by continued growth in Cigna's targeted customer segments.
 Shareholders’ net income for 2018 was $2.6 billion, or $10.54 per share, compared with $2.2 billion, or $8.77 per share, for 2017.
 Cigna's adjusted income from operations2 for 2018 was $3.6 billion, or $14.22 per share, compared with $2.7 billion, or $10.46 per share, for 2017. This reflects increased earnings contributions from each of our segments

En Insurance Information Institute. aparece como 5ª empresa en Top 10 Writers Of Group Life Insurance By Direct Premiums Written, 2018

 También existe Cigna en España

Cigna Life Insurance Company of Europe, S.A./ N.V., Sucursal en España, con domicilio social en Pozuelo de Alarcón (28223 Madrid), Parque Empresarial La Finca, Paseo del Club Deportivo, 1 - Edificio 14 - Planta Baja

Cigna Life Insurance Company of Europe, S.A/N.V. Sucursal en España es una sucursal de Cigna Life Insurance Company of Europe, S.A./N.V. con domicilio social en Bélgica, Avenue Cortenbergh, 52, Bruselas, entidad sometida a la supervisión del Banco Nacional de Bélgica.


Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios

Comentarios